Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

405.00

Mkt cap

93B

Volume

2.6M

High

408.58

P/E Ratio

14.58

52-wk high

567.26

Low

398.69

Div yield

0.02

52-wk low

397.98

JP Morgan analyst Lisa Gill maintains an Overweight rating on Elevance Health (NYSE:ELV) and raises the price target from $628 to $631.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 5:44 pm

Elevance Health (NYSE:ELV) has been analyzed by 12 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target has increased by 3.07% to $595.0. Analysts have recently raised their ratings and price targets, reflecting positive sentiment towards the stock. Key financial metrics such as revenue growth, net margin, ROE, and ROA are strong, although the company faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

May 30, 2024 | 1:00 pm

Baird analyst Michael Ha has initiated coverage on Elevance Health (NYSE:ELV) with an Outperform rating and set a price target of $649.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 9:56 am

UnitedHealth Group Inc. (NYSE:UNH) shares declined significantly after CEO Andrew Witty warned of potential disruptions in the Medicaid market at the Bernstein 40th Annual Strategic Decisions Conference. This announcement also impacted other Medicaid-focused companies like Centene Corp. (NYSE:CNC), Molina Healthcare Inc. (NYSE:MOH), Humana Inc. (NYSE:HUM), and Elevance Health Inc. (NYSE:ELV).

Portfolio Pulse from Vaishali Prayag

May 29, 2024 | 7:57 pm

Elevance Health (NYSE:ELV) has significantly outperformed the market over the past decade, delivering an average annual return of 17.44%. A $100 investment in ELV 10 years ago would now be worth $499.28, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

May 20, 2024 | 8:30 pm

Benzinga's Stock Whisper Index highlights five stocks: Elevance Health, Constellation Energy Corp, SoundHound AI, Howmet Aerospace, and Lumen Technologies. These stocks are identified for their potential as undervalued or emerging opportunities. Elevance Health reported a revenue increase and raised its full-year earnings guidance. Constellation Energy beat EPS estimates but missed on revenue, with shares reaching new highs. SoundHound AI reported a significant revenue increase and beat EPS estimates. Howmet Aerospace also reported higher revenue and raised its full-year guidance. Lumen Technologies, despite a share price drop, highlighted progress in its turnaround strategy.

Portfolio Pulse from Chris Katje

May 10, 2024 | 3:11 pm

Elevance Health (NYSE:ELV) has delivered an average annual return of 15.39% over the past 5 years, outperforming the market by 3.78% annually. With a current market capitalization of $125.43 billion, a $100 investment in ELV 5 years ago would now be worth $202.11. This performance highlights the impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

April 26, 2024 | 6:30 pm

Four health care stocks, Fusion Pharmaceuticals Inc. (FUSN), AstraZeneca PLC (AZN), Boston Scientific Corporation (BSX), and Elevance Health, Inc. (ELV), are identified as overbought based on their RSI values, indicating potential short-term price declines. FUSN's significant gain is due to AstraZeneca's acquisition offer, while AZN, BSX, and ELV have shown strong performance based on recent financial results.

Portfolio Pulse from Avi Kapoor

April 26, 2024 | 12:09 pm

Elevance Health (NYSE:ELV) has seen a 10.89% decrease in short interest, now at 2.09 million shares or 0.9% of float, taking 2.97 days on average to cover. This decline in short interest could indicate a more bullish sentiment towards ELV compared to its peers, where the average short interest as a percentage of float is 4.16%.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 1:00 pm

Analyst ratings for Elevance Health (NYSE:ELV) show a mix of bullish to bearish sentiments among 13 analysts over the last quarter, with a positive shift in the 12-month price targets to an average of $586.0. The company, a leading health insurer in the U.S., has seen a revenue growth rate of 0.96% as of March 31, 2024, and outperforms in net margin and ROE, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 12:01 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.